Latest Articles

Publication Date
All News Scientific
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire

Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire

Published: Feb. 5, 2025, 1:19 p.m.
Read Full Article
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times

Published: Feb. 5, 2025, 1:07 p.m.
Read Full Article
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN

Repare Therapeutics eyes Phase III cancer study after Mythic trial success MSN

Published: Jan. 14, 2025, 11:17 a.m.
Read Full Article
Engineering nanosystems for regulating reproductive health in women.

Reproductive health-related diseases have a significant impact on the well-being of millions of women worldwide, severely compromising their quality of life. Women encounter unique challenges in terms of reproductive health, …

Published: Jan. 1, 2025, midnight
Read Full Article
diagnosis nanomedicine reproductive health regulation treatment woman's reproductive health
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance

Repare Therapeutics eyes Phase III cancer study after Mythic trial success Yahoo Finance

Published: Dec. 13, 2024, 3:28 p.m.
Read Full Article
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News

Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News

Published: Dec. 13, 2024, 12:56 p.m.
Read Full Article
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - BioSpace

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial BioSpace

Published: Dec. 12, 2024, 11:25 p.m.
Read Full Article
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis Seeking Alpha

Published: Dec. 12, 2024, 8:25 p.m.
Read Full Article
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update …

Published: Dec. 4, 2024, 8:10 a.m.
Read Full Article
Karyopharm Therapeutics Provides Endometrial Cancer Program Update - Investor Relations | Karyopharm Therapeutics

Karyopharm Therapeutics Provides Endometrial Cancer Program Update Investor Relations | Karyopharm Therapeutics

Published: Dec. 3, 2024, 12:01 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!